Mark J. Gergen

Companies

• Poseida Therapeutics, Inc.Chief executive officer Feb 1, 2022 to Jan 8, 2025¹
• Poseida Therapeutics, Inc.Board member Jul 9, 2020 to Jan 8, 2025²
• Poseida Therapeutics, Inc.President Jul 9, 2020 to Jan 8, 2025²
• Poseida Therapeutics, Inc.Chair Jan 4, 2024 to Jan 3, 2025³
• Halozyme TherapeuticsChief operating officer Sep 2, 2016 to Feb 24, 2017⁴
• Mirati Therapeutics, Inc.Chief operating officer Jul 12, 2013 to Jan 26, 2016⁵
• Amylin PharmaceuticalsSr VP, Corporate Development Aug 17, 2006 to Feb 24, 2012⁶

Holdings

Stock this person has reported owning, from the forms officers and directors file with the SEC. See the biggest insider stakes.

Shares held

• PTPoseida Therapeutics, Inc.0 shares⁷Jan 8, 2025

As of each latest filing. The line shows shares held over time.

Recent filings

• Jan 8, 2025U 636,726 shares of Poseida Therapeutics, Inc.⁷
• Jan 2, 2025Shares withheld for tax 23,313 shares at $9.60 of Poseida Therapeutics, Inc.⁸
• Dec 10, 2024Sold 30,000 shares at $9.46 of Poseida Therapeutics, Inc.⁹
• Dec 10, 2024Exercised options 30,000 shares at $2.78 of Poseida Therapeutics, Inc.⁹
• Nov 26, 2024Sold 30,000 shares at $9.27 of Poseida Therapeutics, Inc.¹⁰
• Nov 26, 2024Exercised options 30,000 shares at $2.78 of Poseida Therapeutics, Inc.¹⁰
• Mar 1, 2024Shares withheld for tax 34,157 shares at $4.13 of Poseida Therapeutics, Inc.¹¹
• Feb 1, 2024Shares withheld for tax 47,162 shares at $3.41 of Poseida Therapeutics, Inc.¹²
• Jan 2, 2024Granted 125,000 shares of Poseida Therapeutics, Inc.¹³
• Mar 1, 2023Granted 269,586 shares of Poseida Therapeutics, Inc.¹⁴
• Feb 1, 2023Shares withheld for tax 31,819 shares at $7.00 of Poseida Therapeutics, Inc.¹⁵
• Feb 1, 2022Granted 357,200 shares of Poseida Therapeutics, Inc.¹⁶